OHB's Split Personality: Space-Station Science Advances While Shareholders Watch the Meter Run

OHB shares fall 15% weekly despite ISS experiment and €1B Iris² order; analysts see market mechanics, not fundamentals, behind the slide.

The image is almost poetic: a French astronaut floating through the International Space Station, strapped into an electrically stimulating muscle suit developed by a Bremen-based aerospace group. On Tuesday, OHB SE's "EasyMotion-2" experiment officially began operations aboard the ISS with ESA astronaut Sophie Adenot, testing whether electrical muscle stimulation can counteract the wasting effects of weightlessness.

It's the kind of quietly impressive milestone that rarely makes headlines — especially when those headlines are dominated by a share price that has been sliding for weeks.

The stock closed Wednesday at €194.60, down 1.8% on the day, with a weekly decline of roughly 15%. The longer view offers some perspective: the shares remain up 66% since the start of the year. But the recent trajectory tells a different story, one where operational achievements — an ISS qualification, a €1 billion-plus order under Europe's Iris² satellite programme, an unscheduled SDAX index inclusion — have failed to arrest the selling pressure.

What's actually driving the slide

Market observers point to two structural factors rather than any deterioration in the company's fundamentals. The first is a sector-wide correction that followed SpaceX's initial public offering, which has reset sentiment across space-related equities. The second is mechanical: OHB completed a capital increase in June, issuing new shares at €300 apiece while major shareholder KKR sold down existing stock in parallel. The resulting expansion in free float has shifted the supply-demand balance, and the share price has been digesting that overhang ever since.

This distinction matters. A larger share count can depress the price per share regardless of whether the underlying business is delivering. The recent weakness, in other words, may say more about market mechanics than about OHB's operational health.

The numbers behind the narrative

The second-quarter 2026 results, published last month, support that reading. Despite a loss of €0.27 per share, management reaffirmed full-year guidance: total output of around €1.4 billion with an adjusted EBITDA margin between 10.5% and 11%. In a project-based business where upfront costs and milestone billing create lumpy quarterly figures, a negative EPS quarter alongside confirmed guidance is hardly a red flag — it's closer to the norm.

Analysts have taken note. Oddo BHF upgraded the stock from "Neutral" to "Outperform" with a €290 price target, with analyst Stephane Beyazian calling OHB the "best European option in the space race." Jefferies had earlier assigned a "Buy" rating with a €280 target. Both valuations sit well above the current trading level, yet neither endorsement has managed to halt the decline — a sign that technical factors are currently outweighing fundamental reassessment.

A business that keeps delivering

The EasyMotion-2 qualification is part of a broader pattern. The experiment, commissioned by the German Space Agency at DLR, underscores OHB's ability to bring scientific payloads to flight readiness and operate them on the ISS — a capability that distinguishes the company from pure component suppliers. It follows a series of operational wins: the Iris² contract, the SDAX inclusion roughly two weeks ago, and continued progress on the MEO segment of the satellite programme.

Sector-driven volatility has also played a role. Reports about a European satellite network moved the stock in mid-August without any company-specific announcement, and earlier commentary around SpaceX had similarly influenced trading. These external currents appear to be moving the share price more forcefully than individual corporate milestones at present.

Two stories, one company

The situation presents investors with a clear bifurcation. On the operational side, OHB continues to execute — from index inclusion to billion-euro orders to live space-station technology. On the trading side, the stock is working through the consequences of its capital increase and a broader sector recalibration.

For those focused on the company's industrial substance, the current weakness may be more a question of when the market finishes absorbing the new share supply than of whether the business case holds. For shorter-term traders, the enlarged free float could keep supply and demand out of balance for some time yet. The September conference schedule and November's nine-month figures should offer clues as to which of these two narratives ultimately prevails.